Traveling with GLP-1 medications: what the storage rules actually say

What did @itsnicolejanel actually say?

She found an $8 Amazon travel case with gel ice packs, used it to carry her compounded tirzepatide vial to London, and had no problems at security. She brought her prescription, kept it in her carry-on, and skipped pre-filling syringes based on her doctor's advice, because "the pre-filled syrendes might look a little shady since I am on a compound." That's the whole tip. It's practical, low-drama, and grounded in a real conversation with her prescriber.

What she's describing is insulin-style cold chain travel, which is a well-documented practice. The general approach, gel packs, insulated case, documentation in carry-on, is consistent with how diabetic travelers have been managing injectable medications for decades. She's applying that framework to GLP-1 therapy, which is reasonable.

Does the science back this up?

Mostly, yes. The cold storage guidance for tirzepatide is well-established, and the gel pack approach is consistent with manufacturer storage recommendations, with some important caveats about temperature limits that she glosses over.

FDA-approved tirzepatide (Mounjaro, Zepbound) must be stored between 36°F and 46°F (2°C to 8°C) before first use, or at room temperature below 86°F (30°C) for up to 21 days once in use. The concern with gel packs specifically is not that they'll freeze the medication, as she correctly notes, but that poorly calibrated packs can still get medication too close to freezing. Frozen GLP-1 medications are considered compromised and should not be used. A 2021 review by Frid et al. in Diabetes Technology and Therapeutics found that temperature excursions during travel are a real and underreported problem for injectable biologics, with freezing being as damaging as heat exposure. Her claim that the packs "won't freeze the medication" may be true for her specific case, but it's not a guarantee that applies universally to every gel pack product.

What did they get wrong (or right)?

She got the broad strokes right. Carry-on is correct. Documentation is correct. Gel pack cooling is a reasonable approach. The doctor consultation is genuinely good advice that most TikTok health content skips entirely.

Where she's imprecise: compounded tirzepatide is not the same product as FDA-approved tirzepatide, and storage data from Eli Lilly's prescribing information doesn't automatically apply to compounded versions. Compounded peptides can have different stability profiles depending on the formulation, excipients, and compounding pharmacy's quality controls. She treats the cold chain advice as interchangeable, and it may not be. Her compounding pharmacy should be her primary source for storage guidance, not what she's read about the brand-name pen.

Her advice about skipping pre-filled syringes is actually reasonable and doctor-confirmed. TSA allows liquid medications in carry-ons above the 3.4 oz limit, but loose syringes with unlabeled liquid in them are legitimately more likely to prompt questions. Keeping the vial intact with a prescription label is cleaner from a documentation standpoint.

What should you actually know?

If you're traveling with any injectable GLP-1 medication, compounded or brand-name, there are a few things this video doesn't cover that matter. First, TSA's official guidance states that medically necessary liquids are exempt from the 3.4 oz rule, but you should declare them at the checkpoint. Second, international travel adds a layer of complexity: different countries have different rules about importing compounded medications, and a US prescription doesn't automatically grant you entry rights with a vial of unlabeled peptide in a foreign country. London specifically falls under MHRA jurisdiction, and UK customs has its own rules about importing medications not licensed in the UK.

Third, and most importantly, get storage instructions directly from your compounding pharmacy in writing. A paper from Bhatt et al. (2021, Journal of Pharmacy Practice) on compounded injectable stability found meaningful variability in peptide degradation rates depending on formulation, which means generic cold chain rules are a starting point, not a guarantee. Your specific product may have tighter requirements.

The $8 case is fine. The mindset behind it is right. But treat this video as a starting point for your own research, not a complete protocol.